Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.63 USD
Change Today -0.0399 / -5.96%
Volume 105.0K
CYCC On Other Exchanges
Symbol
Exchange
Frankfurt
As of 8:10 PM 08/3/15 All times are local (Market data is delayed by at least 15 minutes).

cyclacel pharmaceuticals inc (CYCC) Snapshot

Open
$0.67
Previous Close
$0.67
Day High
$0.67
Day Low
$0.61
52 Week High
10/28/14 - $3.72
52 Week Low
02/3/15 - $0.51
Market Cap
21.9M
Average Volume 10 Days
104.9K
EPS TTM
$-0.84
Shares Outstanding
34.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CYCLACEL PHARMACEUTICALS INC (CYCC)

Related News

No related news articles were found.

cyclacel pharmaceuticals inc (CYCC) Related Businessweek News

No Related Businessweek News Found

cyclacel pharmaceuticals inc (CYCC) Details

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing small molecule drugs for the treatment of cancer and other serious diseases. The company’s oncology development programs include sapacitabine, an orally-available nucleoside analogue for the treatment of hematological cancers and solid tumors; and seliciclib, an orally-available cyclin dependent kinase (CDK) inhibitor that selectively inhibits a spectrum of enzyme targets comprising CDK2, -7 and -9, which are central to the process of cell division and cell cycle control. Its oncology development programs also comprise CYC065, an orally-available 2nd generation CDK-2, -5, and -9 inhibitor that helps in cancer cell growth, metastatic spread, and DNA damage repair; CYC140, an orally-available small molecule inhibitor of polo-like kinase 1; Sapacitabine + Seliciclib, which is in Phase I trials for the treatment of cancer; and Aurora kinase inhibitors, a serine/threonine protein kinases that focuses on cell division, or mitosis for the treatment of cancer. The company’s non-oncology programs comprise cell cycle inhibitors for the treatment of autoimmune and inflammatory diseases. Cyclacel Pharmaceuticals, Inc. was founded in 1992 and is headquartered in Berkeley Heights, New Jersey.

18 Employees
Last Reported Date: 03/31/15
Founded in 1992

cyclacel pharmaceuticals inc (CYCC) Top Compensated Officers

Chief Executive Officer, President and Execut...
Total Annual Compensation: $530.6K
Chief Operating Officer, Chief Financial Offi...
Total Annual Compensation: $324.4K
Chief Medical Officer and Vice President of C...
Total Annual Compensation: $348.4K
Compensation as of Fiscal Year 2014.

cyclacel pharmaceuticals inc (CYCC) Key Developments

Cyclacel Signs Licensing and Supply Agreement with ManRos

Cyclacel Ltd. and ManRos Therapeutics SA have signed a collaboration, licensing and supply agreement to develop and commercialize Cyclacel's oral seliciclib capsules for the treatment of cystic fibrosis, or CF. Among other terms of the agreement ManRos licensed rights to Cyclacel's proprietary clinical data to enable clinical development of seliciclib for cystic fibrosis indications. The agreement provides for Cyclacel supply of seliciclib investigational product for initial and later stage clinical trials of seliciclib in CF and technical assistance related to Cyclacel's know-how to facilitate these trials. Cyclacel will receive an up-front payment, milestone payments and tiered royalties, if seliciclib is commercialized for the treatment of CF.

Cyclacel Pharmaceuticals, Inc. Announces Dosage of Oral Cyclin Dependent Kinase Inhibitor Seliciclib in Cushing's Disease to the First Patient

Cyclacel Pharmaceuticals, Inc. announced that the first patient has been dosed in an investigator sponsored trial (IST) of the company's oral cyclin dependent kinase (CDK) inhibitor seliciclib in Cushing's disease (CD). Clinicians at Cedars-Sinai, Los Angeles, were awarded a grant from The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to evaluate seliciclib, a CDK2/9 inhibitor currently in clinical development to treat certain cancers, as a potential therapy for CD. CD is an endocrine disorder caused by adrenocorticotropin (ACTH)-producing pituitary tumors, often to obesity, diabetes, hypertension, osteoporosis and increased risk of death if inadequately controlled. Cell cycle dysregulation is a common feature of pituitary tumors, including upregulation of cyclin E, specifically seen in tumors of the corticotroph lineage, such as in CD. Dr. Melmed and Dr. Ning-Ai Liu have previously published preclinical proof-of-concept data showing that seliciclib is uniquely effective amongst CDK inhibitors in resolving the disease, with dual effects on pituitary growth and ACTH production. The trial is a Phase 2 proof-of-concept, open-label, single arm study to assess the safety and efficacy of seliciclib in CD. Sixteen patients with de novo, persistent or recurrent CD will receive seliciclib for 4 weeks prior to standard-of-care treatment. The primary objective is to establish the efficacy of seliciclib on normalizing urinary free cortisol levels in patients with CD. Seliciclib, an orally-available CDK2/9 inhibitor, has been evaluated to date in approximately 450 patients and is currently being explored in combination with Cyclacel's orally-available sapacitabine in patients with solid tumors.

Cyclacel Pharmaceuticals, Inc. Declares Quarterly Cash Dividend on Convertible Exchangeable Preferred Stock, Payable on August 1, 2015

The board of Cyclacel Pharmaceuticals, Inc. declared a quarterly cash dividend in the amount of $0.15 per share on the company's 6% convertible exchangeable preferred stock. The cash dividend will be payable on August 1, 2015 to the holders of record of the preferred stock as of the close of business on July 17, 2015.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CYCC:US $0.63 USD -0.0399

CYCC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CYCC.
View Industry Companies
 

Industry Analysis

CYCC

Industry Average

Valuation CYCC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 9.4x
Price/Book 0.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CYCLACEL PHARMACEUTICALS INC, please visit www.cyclacel.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.